NAPWA

The sponsor company of Sculptra in Australia, Sanofi- Aventis, has finally had confirmation from Medicare that the two item numbers for the injecting procedure have been approved.

The company will be sending advice to relevant doctors shortly, but the expectation is that the listing will be from 1 July. read more »

Following the successful listing of Sculptra (poly-L-lactic acid) on the PBS[Pharmaceutical Benefits Scheme[Pharmaceutical Benefits Scheme] The federal government program which subsidises medication costs in Australia. Anti-HIV drugs are part of a special part of the PBS called Section 100 (S100) which is used for expensive, highly specialised drugs.] The federal government program which subsidises medication costs in Australia. Anti-HIV drugs are part of a special part of the PBS called Section 100 (S100) which is used for expensive, highly specialised drugs. in 2009, many people eligible for the treatment have been eagerly awaiting the listing of an item number to help cover the costs of the procedure.

While the recommendation to list the procedure was made in February last year, there is still no progress on finalising this on the Medicare Benefits Schedule. read more »

The Commonwealth’s recent decision to list Sculptra on the PBS[Pharmaceutical Benefits Scheme[Pharmaceutical Benefits Scheme] The federal government program which subsidises medication costs in Australia. Anti-HIV drugs are part of a special part of the PBS called Section 100 (S100) which is used for expensive, highly specialised drugs.] The federal government program which subsidises medication costs in Australia. Anti-HIV drugs are part of a special part of the PBS called Section 100 (S100) which is used for expensive, highly specialised drugs. is exciting news for Australia’s positive community. Anyone with HIV treatment­associated facial lipoatrophy is now subsidised to receive up to eight vials for their first treatment followed by top­ups of two vials every two years read more »

Today’s PBS[Pharmaceutical Benefits Scheme[Pharmaceutical Benefits Scheme] The federal government program which subsidises medication costs in Australia. Anti-HIV drugs are part of a special part of the PBS called Section 100 (S100) which is used for expensive, highly specialised drugs.] The federal government program which subsidises medication costs in Australia. Anti-HIV drugs are part of a special part of the PBS called Section 100 (S100) which is used for expensive, highly specialised drugs. listing of a treatment for HIV-associated facial wasting will provide substantial improvements in quality of life for people living with HIV, the National Association of People Living with HIV/AIDS (NAPWA) has said. read more »

People with severe facial lipoatrophy caused by HIV treatments are closer to being able to access subsidised treatment with poly-lactic acid under the Pharmaceutical Benefits Scheme[Pharmaceutical Benefits Scheme] The federal government program which subsidises medication costs in Australia. Anti-HIV drugs are part of a special part of the PBS called Section 100 (S100) which is used for expensive, highly specialised drugs. (PBS). read more »

People with facial lipoatrophy are eagerly awaiting the decision by the Pharmaceutical Benefits Advisory Committee to have the facial filler, Sculptra, listed on the Pharmaceutical Benefits Scheme[Pharmaceutical Benefits Scheme] The federal government program which subsidises medication costs in Australia. Anti-HIV drugs are part of a special part of the PBS called Section 100 (S100) which is used for expensive, highly specialised drugs.. read more »

While newer antiretroviralsA medication or other substance which is active against retroviruses such as HIV. do not appear to cause lipoatrophy, the disfiguring side effectAn unwanted effect caused by the administration of drugs. Onset may be sudden or develop over time. characterised by loss of fat from the face and limbs, the problem is still very much with us. David Menadue examins the latest research and treatments. read more »

The annual conference of the Australasian Society for HIV Medicine (ASHMAustralasian Society for HIV Medicine. The peak Australasian organisation representing the medical and health sector in HIV/AIDS and related areas. ) was held in Melbourne in November. This article summarises some key developments. read more »

It’s been three years in the making, but an Australian trial of polylactic acid for the treatment of facial wasting is about to get underway at last. But while the news is good, there are some important limitations to this project. KIRSTY MACHON reports. read more »

The annual Retrovirus Conference is a key event on the HIV scientific calendar, and regularly highlights the most exciting ‘bleeding edge’ developments from the world of HIV science. read more »